The fortunes and perceptions of COVID-19 therapies can change rather quickly. Remdesivir’s journey from presidential praise in the US and huge demand gaps to black marketing (at least in India), and now a setback following a World Health Organization expert panel’s advise against the antiviral’s use in hospitalized patients regardless of disease severity, perhaps captures some of the varying fortunes.
The epitaph of Gilead Sciences, Inc.’s star drug, sold as Veklury, is not by any measure being written. It...






